Breaking News

Financial Report: PAREXEL

April 30, 2014

Revenues up 18% in the quarter

3Q Revenues: $577.9 million (+10%)
3Q Earnings: $34.7 million (+18%)
YTD Revenues: $1.7 billion (+14%)
YTD Earnings: $89.0 million (+35%)
Comments: Clinical Research Services (CRS) revenue was $373.2 million in the quarter, up 9%. PAREXEL Consulting (PC) revenue was $51.9 million, up 3%. PAREXEL Informatics (PI) revenue was $67.3 million, up 9%. Backlog at the end of March 2014 was $4.9 billion, an increase of 9%, including new business wins of $781.6 million in the quarter, and cancellations of $208.7 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks